Designing Shelf-Stable, Dry Powder Vaccines to Improve Global Access and Pandemic Response

Many vaccines require cold chain storage and distribution, limiting their accessibility in resource-poor regions. Dry powder formulations offer a promising solution by eliminating the need for refrigeration. This technology can significantly improve global health, especially in low-income countries heavily burdened by infectious diseases like respiratory infections, malaria, and diarrheal diseases. By making vaccines more accessible, we can effectively combat these diseases and reduce their global impact.

This white paper presents a case study between AAHI and Lonza who have collaborated to develop a dry powder inhalable vaccine for tuberculosis. Using spray drying technology, they produced intranasal dry powder formulations combining the ID93 antigen and GLA-SE adjuvant. The team also assessed the physical properties of the powder and its performance when delivered through intranasal dry powder inhalers. Read the white paper to learn more.

Download the Document

    * denotes a required field

    Please fill out the information below. If you are already registered, and this information will be filled out for you.


  • Please enter your first and last name.

  • Please enter the name of the company or institution you work at.

  • Please enter your mailing address.

  • Please enter the phone number you would like to be contacted at.

  • Please enter the e-mail address you would like to be contacted at.

  • By submitting this form, you consent to Pharmaceutical Outsourcing storing your email address and contact information and transmitting your contact information to the content sponsor. You may request to be removed at any time.